What's New: July 2026 Update TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints Availability unchanged: Retatrutide still investigational, no FDA approval until late 2027 at earliest Tirzepatide still the best available option: 22.5% weight loss, FDA-approved, available today TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program NDA timeline on track: industry estimates continue to expect Q4 2026 filing, following TRIUMPH-1's positive readout Introduction The evolution of weight loss medications has progressed rapidly from single-agonist drugs to multi-agonist approaches
(Contrave contains bupropion )
Nausea management protocol Start implementing these strategies before your first injection, not after nausea hits: Meal sizing: Cut portions by 30 to 50% from day one
Hormone therapy helps with weight loss, energy, muscle building, and overall stamina
A cup of milk has only 8 grams of protein but fills your stomach as much as a cup of Greek yogurt with 20 grams
A meat-based meal does not cause a very big GLP-1 increase, so it doesn't tackle your appetite that effectively, but a vegan meal does, says Barnard, who explores these topics at length in his forthcoming book, The Power Foods Diet
.png)
